Detail akcie Alnylam Pharm online

Business Summary: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Alnylam Pharmaceuticals, Inc. revenues increased 81% to $1.15B. Net loss decreased 82% to $82.8M. Revenues reflect Regeneron Pharmaceuticals segment increase from $17.2M to $234.2M, AMVUTTRA segment increase of 82% to $425.4M, Net revenues from collaborations segment increase from $42.3M to $345.9M, United States segment increase of 36% to $426.4M.